Gut microbiota-derived metabolites play important roles in health and disease.
In this study, we show the pathophysiological role of D-serine in association with the gut microbiota in humans and mice with acute kidney injury.
The results demonstrate the renoprotective effects of D-serine derived from the gut microbiota; shed light on the interactions between the gut microbiota and the kidney; and highlight D-serine as a potential new therapeutic target and biomarker for acute kidney injury.
The kidney is an organ not only for excreting body waste by urine but also for maintaining body homeostasis in close cooperation with other organs.
By producing various hormones, the kidney, for example, generates new erythrocytes in the bone marrow through erythropoietin, maintain bones turnover through activation of vitamin D, and controls blood pressure through the renin-angiotensin system.
In addition, it has recently been shown that the kidney plays an important role in affecting longevity.
However, the relationship of the kidney to the gut (the gut microbiota) has not been studied in detail.
Amino acids exist as enantiomers, i.e., D-amino acids and their L-forms. The term “amino acids” has generally referred to the L-amino acid form or to the mixture of the L- and D- enantiomers.
Recent progress in analytical technologies now makes it possible to distinguish the D-amino acids and their L-forms of about 20 amino acid species that are essential in our body.
These amino acids are referred to as chiral amino acids.
The D-amino acids and their L-forms of an amino acid have the same chemical formula, but are mirror images in three-dimensional structure, analogous to the difference between the left and right hand.
Most interestingly, the D-amino acids and their L-forms differ significantly in their functions in living systems.
L-amino acids are constituents of proteins, one of the most important components of living cells.
On the other hand, the functions and mechanisms of production of D-amino acids are less clear.
Researchers from Kanazawa University, in collaboration with those from Waseda University, RIKEN, Okayama University, Kyushu University and Kitasato University have investigated kidney functions in relation to the gut (the gut microbiota), paying particular attention to the fact that the kidney maintains body homeostasis and the internal environment in cooperation with a number of other organs.
(a) Although some free D-amino acids were detected in the feces of B6 mice with or without I/R, only D-serine can be detected in the kidney. (b) Free D-serine is increased in the feces, plasma, kidney, and urine after the I/R. Credit: Kanazawa University
To assess the effect of acute kidney injury (AKI)) on gut microbiota, we performed gut microbiota analysis with mouse feces after ischemia/reperfusion (I/R) injury to an AKI model.
The gut microbiota were examined to reveal that specific gut bacteria were influenced by AKI (Fig. 1).
In addition, we explored the contribution of the gut microbiota to the pathogenesis of AKI. I/R injury was induced in germ-free (Gf) mice that have no gut microbiota with or without fecal transplantation from normal mice. I/R injury was worse in the Gf B6 mice than in the normal B6 mice.
Interestingly, fecal transplantation from normal mice attenuated the renal pathology in the Gf B6 mice.
These results suggested that the gut microbiota changed due to I/R injury and that possible substance(s) protective for the kidney was produced by the gut microbiota.
Next, in order to identify the substance(s) protecting the kidney against I/R injury produced by gut microbiota, comprehensive analyses of chiral amino acids were performed.
While various D-amino acids were detected in the feces, only D-serine was detected in the kidney (Fig. 2a).
The result suggested that D-serine was produced by the gut microbiota of AKI mice and transported to the kidney via the blood circulation (Fig. 2b).
Furthermore, since D-serine was not detected in the feces of Gf mice, it was suggested that gut microbiota produced D-serine in response to AKI. In addition, D-serine metabolizing enzymes in the kidney were found to increase the D-serine concentration after I/R injury.
Thus, the D-serine concentration in the kidney increased due to augmentation of D-serine production in the kidney in addition to the production of D-serine by the gut microbiota after I/R injury.
Further, in order to examine the effects of D-serine produced by the gut microbiota on the kidney, D-serine dissolved in drinking water was administered to normal mice.
D-Serine is an amino acid found in the brain. Derived from glycine, d-serine is a neuromodulator, meaning it regulates the activities of neurons.
D-Serine supplementation can reduce symptoms of cognitive decline. It is also able to reduce symptoms of diseases characterized by reduced N-methyl-D-aspartate (NMDA) signaling, which includes cocaine dependence and schizophrenia.
D-Serine’s effect on schizophrenia is well researched, and though it shows promise, it is also unreliable, since d-serine does not always reach the blood after supplementation. Sarcosine may be a more reliable treatment.
D-Serine is a coagonist at NDMA receptors, which means it improves the effects of other compounds that bind with the receptor. These compounds include glutamate and NMDA itself.
D-Serine is often categorized as a nootropic.
The oral administration of D-serine mitigated the kidney injury in normal mice and D-serine-depleted mice.
These results showed that D-serine played roles in protecting the kidney from AKI.
Lastly, it was investigated whether similar mechanisms exist in human patients with AKI.
The blood D-serine level of such patients was found to be higher than that of healthy subjects, showing a high correlation with creatinine, one of the markers of renal disorders.
Thus, it was revealed that some gut bacteria respond to AKI, producing D-serine, a substance protective for the kidney, thus affecting the kidney via the blood circulation (Fig. 3).
This study has elucidated the mechanism by which the kidney interacts with gut microbiota through the D-amino acid.
Further, genomic information concerning the gut microbiota that change upon AKI has been deposited in DDBJ/GenBank/EMBL from the present study.
Information on the chiral amino acid analyses has also been published.
These are expected to contribute to further studies on the kidney and the gut microbiota and to more studies of chiral amino acids.
In the future, it will be necessary to establish whether the change of D-amino acid levels due to AKI appear more rapidly than the biomarkers) known so far, and whether analogous mechanisms exist for chronic renal disorders.
The researchers expect that the present study will contribute to the development of biomarkers and medications for AKI based on the utilization of D-amino acids.
More information: Yusuke Nakade et al, Gut microbiota–derived D-serine protects against acute kidney injury, JCI Insight (2018). DOI: 10.1172/jci.insight.97957
Provided by: Kanazawa University search and more info